Zepbound (tirzepatide) is currently the most effective weight loss injection available. In a head-to-head trial published in the New England Journal of Medicine, people taking Zepbound lost 20.2% of their body weight over 72 weeks, compared to 13.7% for those on Wegovy (semaglutide). Both are FDA-approved for chronic weight management, but that roughly 6-percentage-point gap is significant, often translating to 15 or more additional pounds lost.
That said, “best” depends on more than raw efficacy. Cost, side effects, how your body responds, and whether you can stay on the medication long-term all shape real-world results. Here’s what you need to know about each option and how they compare.
How These Shots Work
All current weight loss injections target a hormone system called the incretin pathway, which regulates appetite and blood sugar. The key player is GLP-1, a hormone your gut releases after eating. GLP-1 acts on your brain’s appetite centers in the hypothalamus and brainstem to reduce hunger, slows the rate your stomach empties (so you feel full longer), and improves how your body handles insulin. Wegovy mimics GLP-1 alone.
Zepbound mimics two hormones: GLP-1 and a second gut hormone called GIP. The exact role GIP plays in weight loss is still debated. GIP on its own doesn’t seem to suppress appetite or boost calorie burning. Yet the combination clearly produces greater weight loss than GLP-1 alone, suggesting the two hormones have additive or synergistic effects that researchers are still working to fully explain.
Zepbound vs. Wegovy: The Numbers
The clearest comparison comes from a trial that directly randomized patients to one drug or the other, eliminating the guesswork of comparing separate studies. At 72 weeks, Zepbound users lost an average of 20.2% of their starting weight versus 13.7% for Wegovy users. For someone starting at 250 pounds, that’s roughly 50 pounds lost on Zepbound compared to about 34 on Wegovy.
Both drugs require weekly self-injections, typically in the abdomen, thigh, or upper arm. Both follow a gradual dose-escalation schedule to minimize side effects. Zepbound starts at 2.5 mg weekly, increasing by 2.5 mg every four weeks or longer until reaching a maintenance dose, which can be 5 mg, 10 mg, or up to a maximum of 15 mg. Wegovy follows a similar slow ramp-up over several months. Your prescriber adjusts the dose based on how you respond and what you can tolerate.
Who Can Get a Prescription
Both Zepbound and Wegovy are FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher if you also have at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. You don’t need to have tried other weight loss methods first, but these medications are meant to be used alongside dietary changes and physical activity.
Some medical histories rule out these medications. You should not use them if you have a personal or family history of medullary thyroid cancer or a condition called multiple endocrine neoplasia syndrome type 2 (MEN 2). A history of pancreatitis also calls for caution, as these drugs may worsen inflammation of the pancreas.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. Nausea affects up to 50% of people taking GLP-1-based medications, making it the single most common side effect. Diarrhea is also very common. Vomiting, constipation, abdominal pain, and indigestion occur in a smaller but still notable percentage of users. These symptoms tend to be worst during dose increases and often improve over time as your body adjusts, which is one reason the dose is raised gradually over weeks to months.
Most people tolerate the medications well enough to continue. In clinical trials of earlier GLP-1 drugs, only about 4% of patients stopped treatment specifically because of nausea. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage symptoms during the adjustment period.
Muscle Loss During Treatment
When you lose a significant amount of weight by any method, some of that loss comes from lean muscle rather than fat. With GLP-1-based medications, studies show mixed results: in some trials, lean mass accounted for 40% to 60% of total weight lost, while other studies found it was 15% or less. The wide range likely reflects differences in how much participants exercised and how much protein they consumed.
Resistance training and adequate protein intake are the most effective ways to preserve muscle during treatment. This matters not just for strength and mobility but for long-term metabolic health, since muscle tissue burns more calories at rest than fat does.
What Happens When You Stop
Weight regain after stopping these medications is common and substantial. A systematic review found that within one year of discontinuing a GLP-1-based drug, people regained about 60% of the weight they had lost during treatment. If you lost 50 pounds, you could expect to regain roughly 30 of those pounds within a year of stopping.
This pattern reflects the biology of obesity rather than a failure of willpower. These medications work by suppressing hormonal hunger signals. When the drug is removed, those signals return. For many people, this means weight loss injections are a long-term or even lifelong treatment, similar to blood pressure medication. That makes the cost and tolerability of a given drug especially important considerations.
Cost and Access
Neither medication is cheap. The retail price for Zepbound starts at roughly $299 per month for the lowest dose and climbs to $449 for higher doses through Eli Lilly’s direct-to-consumer pricing. Wegovy falls in a similar range. Recent federal negotiations have brought direct-purchase prices down to an average of about $350 per month without insurance, a reduction from the roughly $500 monthly cost that was standard previously.
Insurance coverage varies widely. Some plans cover these medications for obesity, others only for type 2 diabetes, and many exclude them entirely. Manufacturer savings programs, compounding pharmacies, and employer wellness benefits have expanded access for some patients, but out-of-pocket cost remains a significant barrier, especially given the likelihood of long-term use.
What’s Coming Next
A newer class of injection called a triple agonist targets three hormone receptors instead of two. The most advanced candidate, retatrutide, mimics GLP-1, GIP, and glucagon. In a phase 2 trial, the highest dose produced an average weight loss of 24.2% at 48 weeks, and participants were still losing weight when the trial ended, suggesting even greater reductions are possible with longer treatment. More than 9 out of 10 people on the top dose lost at least 10% of their body weight, and roughly a quarter lost 30% or more.
The glucagon receptor component adds a different mechanism: it acts primarily on the liver to increase fat burning, reduce fat production, and suppress appetite through signals carried by the vagus nerve. Phase 3 trials are ongoing, and retatrutide is not yet FDA-approved, but these results suggest the ceiling for injectable weight loss therapy hasn’t been reached.
Choosing Between the Options
If maximum weight loss is your priority, Zepbound has the strongest evidence. It outperformed Wegovy in a direct comparison, and its dual-hormone approach produces consistently greater results across trials. Wegovy remains a solid option, particularly if your insurance covers it but not Zepbound, or if you experience side effects on one and want to try the other. The two drugs share a similar side effect profile, but individual responses vary, and some people tolerate one better.
The practical reality for most people comes down to three factors: which drug your insurance will pay for, which one you can tolerate without disruptive side effects, and whether you can commit to long-term use. A medication that produces 20% weight loss on paper but that you stop after six months due to cost or nausea will deliver worse real-world results than a slightly less potent option you can sustain.